We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Sir-The advantage of carboplatin in tumours known to demonstrate cisplatinum sensitivity is the prospect of reduced nephro-and ototoxicity. Sleijfer et al. (1989), however, suggested from data derived in adults receiving carboplatin at a dose of 400 mg m-2 that significant reductions of GFR occur. This is contrary to general clinical experience in(More)
  • 1